July 6 (Reuters) - IDORSIA LTD:
* ANNOUNCES POSITIVE RESULTS IN SECOND PHASE 3 STUDY OF DARIDOREXANT
* RESULTS CONFIRM AND REINFORCE EFFICACY AND SAFETY PROFILE FROM FIRST PIVOTAL STUDY
* COMPANY TARGETS FILING NEW DRUG APPLICATION (NDA) AROUND END OF 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.